Abstract | OBJECTIVES: DESIGN: RESULTS: Forty-nine patients received CODOX-M/IVAC and 42 rituximab (R)-CODOX-M/R-IVAC. The addition of rituximab did not confer any significant increase in grade 3/4 toxicities including infections, mucositis, diarrhea, renal impairment, and tumor lysis syndrome. There was no significant difference in toxic deaths between groups (P = 0.14). The 2-year overall survival (OS) was greater for patients receiving rituximab {2-year OS 72% [95% confidence interval (CI) 0.22-0.92, hazard ratio 0.46] vs. 55% [95% CI 1.1-4.5, hazard ratio 2.2]; log-rank P = 0.04}. Similarly, the 2-year progression-free survival (PFS) was greater in the rituximab cohort [2-year PFS 81% (95% CI 0.21-0.99, hazard ratio 0.46) vs. 55% (95% CI 1.0-4.8, hazard ratio 2.2); log-rank P = 0.04]. CONCLUSION:
|
Authors | Ferras Alwan, Annie He, Silvia Montoto, Shireen Kassam, Matthew Mee, Fiona Burns, Simon Edwards, Andrew Wilson, Melinda Tenant-Flowers, Robert Marcus, Kirit M Ardeshna, Mark Bower, Kate Cwynarski |
Journal | AIDS (London, England)
(AIDS)
Vol. 29
Issue 8
Pg. 903-10
(May 15 2015)
ISSN: 1473-5571 [Electronic] England |
PMID | 25730506
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents
- Rituximab
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Methotrexate
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Antiretroviral Therapy, Highly Active
- Burkitt Lymphoma
(drug therapy)
- Cyclophosphamide
(therapeutic use)
- Disease-Free Survival
- Doxorubicin
(therapeutic use)
- Female
- HIV Infections
(drug therapy)
- Humans
- Male
- Methotrexate
(therapeutic use)
- Middle Aged
- Retrospective Studies
- Rituximab
(adverse effects, therapeutic use)
- Treatment Outcome
- Vincristine
(therapeutic use)
- Young Adult
|